BioCentury | Aug 1, 2019
Product Development

NeuBase takes antisense oligos to more targets in more places

...a public listing feasible. NeuBase completed a reverse merger on July 12 with shell company Ohr Pharmaceutical Inc....
BioCentury | Jul 26, 2019
Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

...of NeuBase's PATrOL platform. NeuBase was founded last year and completed a reverse merger with Ohr...
BioCentury | Jul 11, 2019
Company News

July 11 Company Quick Takes: Ono gains Asia rights to Forty Seven's mAb; plus Aimmune, Passage-Paragon and more

...to a Chinese Company" ). Ohr approves reverse merger with NeuBase Shareholders of ophthalmic company Ohr Pharmaceutical Inc....
...Inc. (New York, N.Y.). The companies plan to close the deal next week. In January, Ohr...
...Reverse-Merging With Ohr” ). Paul Bonanos, Associate Editor; Hongjiang Li, Staff Writer Catalent Inc. Forty Seven Inc. NeuBase Therapeutics Inc. Ohr Pharmaceutical Inc. Ono...
BioCentury | Jun 26, 2019
Distillery Therapeutics

Inhibiting PTP-1B to improve islet graft outcomes for Type I diabetes

...Inc. has the PTP-1B antisense oligonucleotide IONIS-PTP1BRx in Phase II testing for Type II diabetes. Ohr Pharmaceutical Inc....
BioCentury | Feb 28, 2019
Distillery Therapeutics

Neurology

...decreased motor impairment. Next steps could include testing trodusquemine in additional animal models of AD. Ohr Pharmaceutical Inc....
BioCentury | Jan 4, 2019
Company News

Gene silencing company NeuBase reverse-merging with Ohr

...Ophthalmic company Ohr Pharmaceutical Inc. (NASDAQ:OHRP) will reverse-merge with gene silencing company NeuBase Therapeutics Inc. (New York, N.Y...
...oligonucleotide (PATrOL) platform. NeuBase shareholders are expected to own 80% of the merged company and Ohr...
...Ohr Pharmaceutical Inc. (NASDAQ:OHRP), New York, N.Y. NeuBase Therapeutics Inc., New York, N.Y. Business: Gene/Cell therapy Elizabeth S. Eaton Ohr Pharmaceutical Inc. NeuBase...
BioCentury | Jul 13, 2018
Clinical News

Cold Harbor JV developing copper chelator for Wilson's disease

...DepYmed Inc., a joint venture between Cold Spring Harbor Laboratory and Ohr Pharmaceutical Inc. (NASDAQ:OHRP), is developing its...
...other programs. No other companies have PTP-1B-targeting candidates in development, according to BioCentury's BCIQ database. Ohr Pharmaceutical Inc....
...Cold Spring Harbor, N.Y. Product: DPM-1001 Business: Endocrine/Metabolic Indication: Treat Wilson's disease Jennie Walters Cold Spring Harbor Laboratory Ohr Pharmaceutical Inc. Protein...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...OTX-TP) Open-angle glaucoma or ocular hypertension Ph III data 2H18 Ohr Pharmaceutical Inc. (NASDAQ:OHRP) Squalamine eye drops (OHR-102...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...Ocular Therapeutix Inc. (NASDAQ:OCUL) Dextenza dexamethasone insert Ocular pain following ophthalmic surgery PDUFA date 7/19/17 Ohr Pharmaceutical Inc....
BioCentury | Jul 7, 2017
Finance

Generalists needed

...Inc. (NASDAQ:CDXS) 4/7/17 $25.3 $190.8 $262.5 38% FibroGen Inc. (NASDAQ:FGEN) 4/6/17 $120.0 $1,598.5 $2,259.2 41% Ohr Pharmaceutical Inc....
Items per page:
1 - 10 of 59
BioCentury | Aug 1, 2019
Product Development

NeuBase takes antisense oligos to more targets in more places

...a public listing feasible. NeuBase completed a reverse merger on July 12 with shell company Ohr Pharmaceutical Inc....
BioCentury | Jul 26, 2019
Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

...of NeuBase's PATrOL platform. NeuBase was founded last year and completed a reverse merger with Ohr...
BioCentury | Jul 11, 2019
Company News

July 11 Company Quick Takes: Ono gains Asia rights to Forty Seven's mAb; plus Aimmune, Passage-Paragon and more

...to a Chinese Company" ). Ohr approves reverse merger with NeuBase Shareholders of ophthalmic company Ohr Pharmaceutical Inc....
...Inc. (New York, N.Y.). The companies plan to close the deal next week. In January, Ohr...
...Reverse-Merging With Ohr” ). Paul Bonanos, Associate Editor; Hongjiang Li, Staff Writer Catalent Inc. Forty Seven Inc. NeuBase Therapeutics Inc. Ohr Pharmaceutical Inc. Ono...
BioCentury | Jun 26, 2019
Distillery Therapeutics

Inhibiting PTP-1B to improve islet graft outcomes for Type I diabetes

...Inc. has the PTP-1B antisense oligonucleotide IONIS-PTP1BRx in Phase II testing for Type II diabetes. Ohr Pharmaceutical Inc....
BioCentury | Feb 28, 2019
Distillery Therapeutics

Neurology

...decreased motor impairment. Next steps could include testing trodusquemine in additional animal models of AD. Ohr Pharmaceutical Inc....
BioCentury | Jan 4, 2019
Company News

Gene silencing company NeuBase reverse-merging with Ohr

...Ophthalmic company Ohr Pharmaceutical Inc. (NASDAQ:OHRP) will reverse-merge with gene silencing company NeuBase Therapeutics Inc. (New York, N.Y...
...oligonucleotide (PATrOL) platform. NeuBase shareholders are expected to own 80% of the merged company and Ohr...
...Ohr Pharmaceutical Inc. (NASDAQ:OHRP), New York, N.Y. NeuBase Therapeutics Inc., New York, N.Y. Business: Gene/Cell therapy Elizabeth S. Eaton Ohr Pharmaceutical Inc. NeuBase...
BioCentury | Jul 13, 2018
Clinical News

Cold Harbor JV developing copper chelator for Wilson's disease

...DepYmed Inc., a joint venture between Cold Spring Harbor Laboratory and Ohr Pharmaceutical Inc. (NASDAQ:OHRP), is developing its...
...other programs. No other companies have PTP-1B-targeting candidates in development, according to BioCentury's BCIQ database. Ohr Pharmaceutical Inc....
...Cold Spring Harbor, N.Y. Product: DPM-1001 Business: Endocrine/Metabolic Indication: Treat Wilson's disease Jennie Walters Cold Spring Harbor Laboratory Ohr Pharmaceutical Inc. Protein...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...OTX-TP) Open-angle glaucoma or ocular hypertension Ph III data 2H18 Ohr Pharmaceutical Inc. (NASDAQ:OHRP) Squalamine eye drops (OHR-102...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...Ocular Therapeutix Inc. (NASDAQ:OCUL) Dextenza dexamethasone insert Ocular pain following ophthalmic surgery PDUFA date 7/19/17 Ohr Pharmaceutical Inc....
BioCentury | Jul 7, 2017
Finance

Generalists needed

...Inc. (NASDAQ:CDXS) 4/7/17 $25.3 $190.8 $262.5 38% FibroGen Inc. (NASDAQ:FGEN) 4/6/17 $120.0 $1,598.5 $2,259.2 41% Ohr Pharmaceutical Inc....
Items per page:
1 - 10 of 59